Glenmark Pharmaceuticals has launched Phytonadione injectable emulsion through its US arm, targeting anticoagulant markets. The 10 mg/mL single-dose ampules are bioequivalent to Vitamin K1 Injectable Emulsion USP. This launch diversifies Glenmark's institutional product portfolio and reinforces their commitment to offering affordable alternatives, with the market valued at approximately USD 19.7 million annually. Glenmark Pharmaceuticals on Tuesday said its US arm has launched anticoagulant Phytonadione injectable emulsion. Glenmark Pharmaceuticals Inc., USA has launched Phytonadione injectable emulsion of strength 10 mg/mL single-dose ampules, the company said in a statement. The single-dose ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, Inc., it added.
Commenting on the launch, Glenmark President & Business Head, North America Marc Kikuchi said, it grows the company's ""portfolio of products within the institutional channel, while also strengthening our commitment to bring to market
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!